NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
American International Group Inc., up $3.19 to $50.30
The insurer reported solid underwriting gains in the...
Weight Watchers plunges, Best Buy and Campbell Soup jump
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Wednesday:
Weight Watchers International Inc., down $10.20 to $19.37
Snap and Hostess skid while Match and CVS jump
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday:
Match Group Inc., up $6.72 to $45.60
The online dating company's results were better than investors expected.
Snap Inc., down 89 cents to $12.23
The online video chat company said it lost daily users in the second quarter.
Avis Budget Group Inc., down $5.88 to $32.85
The rental car company lowered its revenue forecast after a weak second quarter.
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday:
Starbucks Corp., down $1.39 to $55.68
Howard Schultz is stepping down as the coffee chain's executive chairman.
G-III Apparel Group Ltd., up $4.65 to $47.53
The clothing and accessories company raised its annual forecasts after a strong quarter.
Mylan NV, up $1.48 to $39.98
The FDA approved Mylan's version of Amgen's drug Neulasta.
Ulta Beauty and Qualcomm slip while Ford and Blue Apron jump
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:
Qualcomm Inc., down 85 cents to $65.49
Bloomberg News reported that rival chipmaker Broadcom doesn't plan to make a new offer for Qualcomm until next year.
Blue Apron Holdings Inc., up 24 cents to $3.23
The meal kit company said it is replacing its CEO.
Ulta Beauty Inc., down $9.13 to $212.58
The beauty products company's fourth-quarter forecasts disappointed Wall Street.
After harsh light, a cheaper version of EpiPen from Mylan
Mylan is releasing a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew scorn from parents nationwide and spawned Congressional inquiries.
The potential cost savings will depend in part on a patient's insurance coverage and qualifications for discount and assistance programs that the drugmaker also provides.
US lawmakers blast Mylan CEO over ‘sickening’ EpiPen price hikes
(Reuters) — U.S. lawmakers on Wednesday blasted Mylan NV Chief Executive Heather Bresch for sharply increasing prices for the EpiPen emergency allergy treatment at a congressional hearing in which Republicans and Democrats questioned the reasons behind rising U.S. drug costs.
Source: HealthGrove | Graphiq
Source: FindTheCompany | Graphiq
Starboard buys stake in drugmaker Perrigo, wants shakeup
NEW YORK (AP) — Activist investor Starboard Value said Monday that it bought a 4.6 percent stake in Perrigo and pushed the Irish drugmaker to shake up its business.
In a letter to Perrigo's management, Starboard said that the company's performance has been "poor" and that it needs to make changes to create value for shareholders. Starboard said Perrigo's plans last year to improve the company on its own after it rejected a takeover bid from rival Mylan NV did not pan out.